Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “Aligos Therapeutics, Inc.”

32 pharma patents match "Aligos Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 32
Index total 30,257
Page 1 / 2

Quick answer

This filtered view shows 32 pharmaceutical patents matching "Aligos Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

32 results for “Aligos Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 12384779

    Bicyclic compounds

    Aligos Therapeutics, Inc. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  2. US 12252481

    Anti-viral compounds

    Aligos Therapeutics, Inc. · Granted Mar 18, 2025 · Expires Mar 13, 2045

    granted
  3. US 12180192

    Modulators of THR-β and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Dec 31, 2024 · Expires Dec 26, 2044

    granted
  4. US 12129469

    Modified short interfering nucleic acid (siNA) molecules and uses thereof

    Aligos Therapeutics, Inc. · Granted Oct 29, 2024 · Expires Oct 24, 2044

    granted
  5. US 12065428

    Anti-viral compounds

    Aligos Therapeutics, Inc. · Granted Aug 20, 2024 · Expires Aug 15, 2044

    granted
  6. US 12018015

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Jun 25, 2024 · Expires Jun 20, 2044

    granted
  7. US 11957683

    Bicyclic compounds

    Aligos Therapeutics, Inc. · Granted Apr 16, 2024 · Expires Apr 11, 2044

    granted
  8. US 11952374

    Bicyclic compounds

    Aligos Therapeutics, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  9. US 11952365

    Anti-viral compounds

    Aligos Therapeutics, Inc. · Granted Apr 9, 2024 · Expires Apr 4, 2044

    granted
  10. US 11939581

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Mar 26, 2024 · Expires Mar 21, 2044

    granted
  11. US 11858913

    Bicyclic pyridazinones and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  12. US 11851422

    Anti-viral compounds

    Aligos Therapeutics, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  13. US 11845752

    Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B

    Aligos Therapeutics, Inc. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  14. US 11840532

    Modulators of THR-β and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  15. US 11820773

    Tricyclic compounds

    Aligos Therapeutics, Inc. · Granted Nov 21, 2023 · Expires Nov 16, 2043

    granted
  16. US 11793815

    Oxindoles and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Oct 24, 2023 · Expires Oct 19, 2043

    granted
  17. US 11786532

    2-pyridones and methods of use thereof

    Aligos Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  18. US 11787833

    Modified cyclic dinucleoside compounds as sting modulators

    Aligos Therapeutics, Inc. · Granted Oct 17, 2023 · Expires Oct 12, 2043

    granted
  19. US 11771680

    Pyrrole compounds

    Aligos Therapeutics, Inc. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  20. US 11760761

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  21. US 11760764

    Methods and compositions for targeting PD-L1

    Aligos Therapeutics, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  22. US 11613750

    Methods of reducing virus molecule levels

    Aligos Therapeutics, Inc. · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  23. US 11591341

    Bicyclic and tricyclic compounds

    Aligos Therapeutics, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  24. US 11549110

    Modified short interfering nucleic acid (siNA) molecules and uses thereof

    Aligos Therapeutics, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted